0001493152-22-021598.txt : 20220927 0001493152-22-021598.hdr.sgml : 20220927 20220808153856 ACCESSION NUMBER: 0001493152-22-021598 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bioAffinity Technologies, Inc. CENTRAL INDEX KEY: 0001712762 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 465211056 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 BUSINESS PHONE: 210-698-5334 MAIL ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 CORRESP 1 filename1.htm

August 8, 2022

United States Securities and Exchange Commission

Office of Trade & Services

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Ms. Taylor Beech

	Re:	bioAffinity Technologies, Inc.
		Registration Statement on Form S-1, File No. 333-264463
		Registration Statement on Form 8-A, File No. 001-41463

REQUEST FOR ACCELERATION OF EFFECTIVENESS

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), bioAffinity Technologies, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statements on Form S-1, as amended, and Form 8-A be accelerated to 4:30 p.m., Eastern Daylight Time, on Tuesday, August 9, 2022, or as soon thereafter as practicable unless we or our outside counsel, Dykema Gossett PLLC, request by telephone that such Registration Statements be declared effective at some other time.

In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statements are effective, please orally confirm the event with our counsel, Dykema Gossett PLLC by calling Wilhelm E. Liebmann at (210) 554-5414. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statements be sent to our counsel, Dykema Gossett PLLC, Attention: Wilhelm E. Liebmann by email to wliebmann@dykema.com.

If you have any questions regarding this request, please contact Wilhelm E. Liebmann of Dykema Gossett PLLC at (210) 554-5414.

	Very truly yours,

	BIOAFFINITY TECHNOLOGIES, INC.

	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	Chief Executive Officer